Epidermal growth factor receptor mutations in lung cancer (original) (raw)

• Brambilla, E., Travis, W. D., Colby, T. V., Corrin, B. & Shimosato, Y. The new World Health Organization classification of lung tumours. Eur. Respir. J. 18, 1059–1068 (2001).
  Article CAS PubMed Google Scholar
• Rapp, E. et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer — report of a Canadian multicenter randomized trial. J. Clin. Oncol. 6, 633–641 (1988).
  Article CAS PubMed Google Scholar
• Breathnach, O. S. et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J. Clin. Oncol. 19, 1734–1742 (2001).
  Article CAS PubMed Google Scholar
• Blackhall, F. H., Shepherd, F. A. & Albain, K. S. Improving survival and reducing toxicity with chemotherapy in advanced non-small cell lung cancer: a realistic goal? Treat Respir. Med. 4, 71–84 (2005).
  Article CAS PubMed Google Scholar
• Blackhall, F., Ranson, M. & Thatcher, N. Where next for gefitinib in patients with lung cancer? Lancet Oncol. 7, 499–507 (2006).
  Article CAS PubMed Google Scholar
• Krause, D. S. & Van Etten, R. A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med. 353, 172–187 (2005).
  Article CAS PubMed Google Scholar
• Hynes, N. E. & Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Rev. Cancer 5, 341–354 (2005).
  Article CAS Google Scholar
• Nicholson, R. I., Gee, J. M. & Harper, M. E. EGFR and cancer prognosis. Eur. J. Cancer 37 (Suppl. 4), S9–S15 (2001).
  Article CAS PubMed Google Scholar
• Veale, D., Ashcroft, T., Marsh, C., Gibson, G. J. & Harris, A. L. Epidermal growth factor receptors in non-small cell lung cancer. Br. J. Cancer 55, 513–516 (1987).
  Article CAS PubMed PubMed Central Google Scholar
• Haeder, M. et al. Epidermal growth factor receptor expression in human lung cancer cell lines. Cancer Res. 48, 1132–1136 (1988).
  CAS PubMed Google Scholar
• Ohsaki, Y. et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol. Rep. 7, 603–607 (2000).
  CAS PubMed Google Scholar
• Hirsch, F. R. et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21, 3798–3807 (2003).
  Article CAS PubMed Google Scholar
• Testa, J. R. & Siegfried, J. M. Chromosome abnormalities in human non-small cell lung cancer. Cancer Res. 52, 2702s–2706s (1992).
  CAS PubMed Google Scholar
• Putnam, E. A. et al. Autocrine growth stimulation by transforming growth factor-α in human non-small cell lung cancer. Surg. Oncol. 1, 49–60 (1992).
  Article CAS PubMed Google Scholar
• Rusch, V. et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 53, 2379–2385 (1993).
  CAS PubMed Google Scholar
• Mendelsohn, J. Epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. J. Natl Cancer Inst. Monogr. 125–131 (1992).
• Giaccone, G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J. Clin. Oncol. 23, 3235–3242 (2005).
  Article CAS PubMed Google Scholar
• Barker, A. J. et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 11, 1911–1914 (2001).
  Article CAS PubMed Google Scholar
• Wakeling, A. E. et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62, 5749–5754 (2002).
  CAS PubMed Google Scholar
• Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139 (2004). Identified mutations in the ATP-binding pocket of EGFR that confer hypersensitivity to gefitinib and translates to a gefitinib response accompanied by tumour shrinkage in patients with NSCLC in a clinical setting.
  Article CAS PubMed Google Scholar
• Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500 (2004). Identified mutations in the kinase domain of EGFR that predict gefitinib response.
  Article CAS PubMed Google Scholar
• Pao, W. et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306–13311 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Sequist, L. V. et al. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin. Cancer Res. 12, 4403s–4408s (2006).
  Article CAS PubMed Google Scholar
• Settleman, J. Mutant kinases as targets for cancer drugs. Drug Discov. Today Dis. Mech. 2, 139–144 (2005).
  Article CAS Google Scholar
• Kosaka, T. et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 64, 8919–8923 (2004).
  Article CAS PubMed Google Scholar
• Janne, P. A., Engelman, J. A. & Johnson, B. E. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J. Clin. Oncol. 23, 3227–3234 (2005).
  Article CAS PubMed Google Scholar
• Shigematsu, H. et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl Cancer Inst. 97, 339–346 (2005).
  Article CAS PubMed Google Scholar
• Han, S. W. et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 23, 2493–2501 (2005).
  Article CAS PubMed Google Scholar
• Marchetti, A. et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 23, 857–865 (2005).
  Article CAS PubMed Google Scholar
• Mitsudomi, T. et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23, 2513–2520 (2005).
  Article CAS PubMed Google Scholar
• Cappuzzo, F. et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl Cancer Inst. 97, 643–655 (2005).
  Article CAS PubMed Google Scholar
• Tsao, M. S. et al. Erlotinib in lung cancer- molecular and clinical predictors of outcome. N. Engl J. Med. 353, 133–144 (2005).
  Article CAS PubMed Google Scholar
• Chou, T. Y. et al. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin. Cancer Res. 11, 3750–3757 (2005).
  Article CAS PubMed Google Scholar
• Haneda, H. et al. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. Jpn J. Clin. Oncol. 36, 69–75 (2006).
  Article PubMed Google Scholar
• Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786–792 (2005). Identified a second site intragenic mutation in EGFR (T790M) that confers acquired resistance to gefitinib in patients with NSCLC that stop responding to gefitinib therapy.
  Article CAS PubMed Google Scholar
• Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005). Identified the T790M mutation in exon 20 of EGFR that confers acquired resistance to EGFR-TKIs.
  Article PubMed PubMed Central CAS Google Scholar
• Kwak, E. L. et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl Acad. Sci. USA 102, 7665–7670 (2005). In vitro data showing that T790M-mediated acquired resistance to gefitinib can be overcome by irreversible EGFR-TKIs.
  Article CAS PubMed PubMed Central Google Scholar
• Gow, C. H., Shih, J. Y., Chang, Y. L. & Yu, C. J. Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R. PLoS Med. 2, e269 (2005).
  Article PubMed PubMed Central Google Scholar
• Inukai, M. et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 66, 7854–7858 (2006).
  Article CAS PubMed Google Scholar
• Greulich, H. et al. Oncogenic transformation by inhibitor-sensitive and-resistant EGFR mutants. PLoS Med. 2, e313 (2005).
  Article PubMed PubMed Central CAS Google Scholar
• Ji, H. et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9, 485–495 (2006). Showed the relevance of EGFR mutations to the development of NSCLC and response to EGFR-TKIs in a mouse tumour model.
  Article CAS PubMed Google Scholar
• Politi, K. et al. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 20, 1496–1510 (2006). Modelled NSCLC in mice using transgenic kinase domain mutant EGFR and showed their response to EGFR-TKIs.
  Article CAS PubMed PubMed Central Google Scholar
• Sordella, R., Bell, D. W., Haber, D. A. & Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163–1167 (2004). EGFR kinase domain mutations hyperactivate survival pathways such as Akt and STAT 3, and gefitinib attenuates them in sensitive cell lines.
  Article CAS PubMed Google Scholar
• Jiang, J. et al. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 65, 8968–8974 (2005).
  Article CAS PubMed Google Scholar
• Prudkin, L. & Wistuba, II. Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications. Ann. Diagn. Pathol. 10, 306–315 (2006).
  Article PubMed Google Scholar
• Kobayashi, S. et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 65, 7096–7101 (2005).
  Article CAS PubMed Google Scholar
• Nagatomo, I. et al. The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell line. DNA Cell Biol. 25, 246–251 (2006).
  Article CAS PubMed Google Scholar
• Carey, K. D. et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 66, 8163–8171 (2006).
  Article CAS PubMed Google Scholar
• Mulloy, R. et al. EGF receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res. (in the press).
• Fabian, M. A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nature Biotechnol. 23, 329–336 (2005).
  Article CAS Google Scholar
• Okamoto, I. et al. EGFR mutation in gefitinib-responsive small-cell lung cancer. Ann. Oncol. 17, 1028–1029 (2006).
  Article CAS PubMed Google Scholar
• Gwak, G. Y. et al. Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas. J. Cancer Res. Clin. Oncol. 131, 649–652 (2005).
  Article CAS PubMed Google Scholar
• Schilder, R. J. et al. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin. Cancer Res. 11, 5539–5548 (2005).
  Article CAS PubMed Google Scholar
• Barber, T. D., Vogelstein, B., Kinzler, K. W. & Velculescu, V. E. Somatic mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med. 351, 2883 (2004).
  Article CAS PubMed Google Scholar
• Lee, J. W. et al. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clin. Cancer Res. 11, 2879–2882 (2005).
  Article CAS PubMed Google Scholar
• Kwak, E. L. et al. Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin. Cancer Res. 12, 4283–4287 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Fukuoka, M. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol. 21, 2237–2246 (2003).
  Article CAS PubMed Google Scholar
• Kris, M. G. et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290, 2149–2158 (2003).
  Article CAS PubMed Google Scholar
• Shepherd, F. A. et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353, 123–132 (2005). Reports on a phase III clinical trial that showed a significant survival benefit for individuals with advanced NSCLC who were treated with erlotinib.
  Article CAS PubMed Google Scholar
• Perez-Soler, R. et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 22, 3238–3247 (2004).
  Article CAS PubMed Google Scholar
• Bell, D. W. et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J. Clin. Oncol. 23, 8081–8092 (2005).
  Article CAS PubMed Google Scholar
• Cortes-Funes, H. et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann. Oncol. 16, 1081–1086 (2005).
  Article CAS PubMed Google Scholar
• Huang, S. F. et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. 10, 8195–8203 (2004).
  Article CAS PubMed Google Scholar
• Kim, K. S. et al. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin. Cancer Res. 11, 2244–2251 (2005).
  Article CAS PubMed Google Scholar
• Kondo, M. et al. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. Lung Cancer 50, 385–391 (2005).
  Article PubMed Google Scholar
• Mu, X. L. et al. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Clin. Cancer Res. 11, 4289–4294 (2005).
  Article CAS PubMed Google Scholar
• Niho, S. et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J. Clin. Oncol. 24, 64–69 (2006).
  Article CAS PubMed Google Scholar
• Rosell, R. et al. Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer 50, 25–33 (2005).
  Article PubMed Google Scholar
• Takano, T. et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23, 6829–6837 (2005).
  Article CAS PubMed Google Scholar
• Taron, M. et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin. Cancer Res. 11, 5878–5885 (2005).
  Article CAS PubMed Google Scholar
• Tokumo, M. et al. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer. Lung Cancer 53, 117–121 (2006).
  Article PubMed Google Scholar
• Tomizawa, Y. et al. Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer. Clin. Cancer Res. 11, 6816–6822 (2005).
  Article CAS PubMed Google Scholar
• Zhang, X. T. et al. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann. Oncol. 16, 1334–1342 (2005).
  Article PubMed Google Scholar
• Jackman, D. M. et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin. Cancer Res. 12, 3908–3914 (2006).
  Article CAS PubMed Google Scholar
• Riely, G. J. et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 12, 839–844 (2006).
  Article CAS PubMed Google Scholar
• Tokumo, M. et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin. Cancer Res. 11, 1167–1173 (2005).
  CAS PubMed Google Scholar
• Hirsch, F. R. et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J. Clin. Oncol. 23, 6838–6845 (2005).
  Article CAS PubMed Google Scholar
• Cappuzzo, F. et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J. Clin. Oncol. 23, 5007–5018 (2005).
  Article CAS PubMed Google Scholar
• Cappuzzo, F. et al. HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients. Br. J. Cancer 93, 1334–1340 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Suzuki, R. et al. A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer. Br. J. Cancer 94, 1599–1603 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Inoue, A. et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J. Clin. Oncol. 24, 3340–3346 (2006).
  Article CAS PubMed Google Scholar
• Hirsch, F. R. et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J. Clin. Oncol. 24, 5034–42 (2006).
  Article CAS PubMed Google Scholar
• Thatcher, N. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527–1537 (2005). Reports on a phase III clinical trial that showed a lack of survival benefit in individuals with advanced NSCLC who were treated with gefitinib.
  Article CAS PubMed Google Scholar
• Ono, M. et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol. Cancer Ther. 3, 465–472 (2004).
  CAS PubMed Google Scholar
• Han, S. W. et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int. J. Cancer 113, 109–115 (2005).
  Article CAS PubMed Google Scholar
• Mukohara, T. et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J. Natl Cancer Inst. 97, 1185–1194 (2005).
  Article CAS PubMed Google Scholar
• Anderson, N. G., Ahmad, T., Chan, K., Dobson, R. & Bundred, N. J. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int. J. Cancer 94, 774–782 (2001).
  Article CAS PubMed Google Scholar
• Moasser, M. M., Basso, A., Averbuch, S. D. & Rosen, N. The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 61, 7184–7188 (2001).
  CAS PubMed Google Scholar
• She, Q. B., Solit, D., Basso, A. & Moasser, M. M. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3′-kinase/Akt pathway signaling. Clin. Cancer Res. 9, 4340–4346 (2003).
  CAS PubMed Google Scholar
• Engelman, J. A. et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl Acad. Sci. USA 102, 3788–3793 (2005). Gefitinib sensitivity is correlated with the heterodimerization of EGFR with ERBB2 and the attenuation of Akt activation in gefitinib-treated NSCLC cell lines.
  Article CAS PubMed PubMed Central Google Scholar
• Weinstein, I. B. Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. Carcinogenesis 21, 857–864 (2000).
  Article CAS PubMed Google Scholar
• Sharma, S. V. et al. A common signaling cascade may underlie 'addiction' to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10, 425–435 (2006). Details the molecular mechanistic basis for cancer cell killing by oncogene-targeted therapeutics.
  Article CAS PubMed PubMed Central Google Scholar
• Evan, G. & Littlewood, T. A matter of life and cell death. Science 281, 1317–1322 (1998).
  Article CAS PubMed Google Scholar
• Chen, C. Y. & Faller, D. V. Direction of p21ras-generated signals towards cell growth or apoptosis is determined by protein kinase C and Bcl-2. Oncogene 11, 1487–1498 (1995).
  CAS PubMed Google Scholar
• Mayo, M. W. et al. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278, 1812–1815 (1997).
  Article CAS PubMed Google Scholar
• Johnson, D. et al. Regulation of both apoptosis and cell survival by the v-Src oncoprotein. Cell Death Differ. 7, 685–696 (2000).
  Article CAS PubMed Google Scholar
• Webb, B. L., Jimenez, E. & Martin, G. S. v-Src generates a p53-independent apoptotic signal. Mol. Cell. Biol. 20, 9271–9280 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, J. Y. Regulation of cell death by the Abl tyrosine kinase. Oncogene 19, 5643–5650 (2000).
  Article CAS PubMed Google Scholar
• Reginato, M. J. et al. Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nature Cell Biol. 5, 733–740 (2003).
  Article CAS PubMed Google Scholar
• Evan, G. I. et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 69, 119–128 (1992).
  Article CAS PubMed Google Scholar
• Shi, Y. et al. Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 257, 212–214 (1992).
  Article CAS PubMed Google Scholar
• White, E. & Stillman, B. Expression of adenovirus E1B mutant phenotypes is dependent on the host cell and on synthesis of E1A proteins. J. Virol. 61, 426–435 (1987).
  CAS PubMed PubMed Central Google Scholar
• Rodenhuis, S. et al. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N. Engl. J. Med. 317, 929–935 (1987).
  Article CAS PubMed Google Scholar
• Mitsudomi, T. et al. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res. 51, 4999–5002 (1991).
  CAS PubMed Google Scholar
• Husgafvel-Pursiainen, K. et al. K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. Int. J. Cancer 53, 250–256 (1993).
  Article CAS PubMed Google Scholar
• Ahrendt, S. A. et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92, 1525–1530 (2001).
  Article CAS PubMed Google Scholar
• Soung, Y. H. et al. Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch. 446, 483–488 (2005).
  Article CAS PubMed Google Scholar
• Pao, W. et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17 (2005). Shows the correlation between the presence of activated KRAS with NSCLC insensitivity to EGFR-TKIs.
  Article PubMed PubMed Central CAS Google Scholar
• Cully, M., You, H., Levine, A. J. & Mak, T. W. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nature Rev. Cancer 6, 184–192 (2006).
  Article CAS Google Scholar
• Kohno, T., Takahashi, M., Manda, R. & Yokota, J. Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer 22, 152–156 (1998).
  Article CAS PubMed Google Scholar
• Soria, J. C. et al. Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin. Cancer Res. 8, 1178–1184 (2002).
  CAS PubMed Google Scholar
• Bianco, R. et al. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22, 2812–2822 (2003).
  Article CAS PubMed Google Scholar
• Chakravarti, A., Loeffler, J. S. & Dyson, N. J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 62, 200–207 (2002).
  CAS PubMed Google Scholar
• Hurbin, A., Dubrez, L., Coll, J. L. & Favrot, M. C. Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines. J. Biol. Chem. 277, 49127–49133 (2002).
  Article CAS PubMed Google Scholar
• Erjala, K. et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin. Cancer Res. 12, 4103–4111 (2006).
  Article CAS PubMed Google Scholar
• Cappuzzo, F. et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann. Oncol. 17, 1120–1127 (2006).
  Article CAS PubMed Google Scholar
• Kosaka, T. et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin. Cancer Res. 12, 5764–5769 (2006).
  Article CAS PubMed Google Scholar
• Engelman, J. A. et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 116, 2695–2706 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Bell, D. W. et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nature Genet. 37, 1315–1316 (2005). Shows that the T790M mutation that confers acquired resistance to EGFR-TKIs might also predispose individuals to develop NSCLC.
  Article CAS PubMed Google Scholar
• Shih, J. Y., Gow, C. H. & Yang, P. C. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer. N. Engl. J. Med. 353, 207–208 (2005).
  Article CAS PubMed Google Scholar
• Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876–880 (2001).
  Article CAS PubMed Google Scholar
• Blencke, S. et al. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem. Biol. 11, 691–701 (2004).
  Article CAS PubMed Google Scholar
• Daub, H., Specht, K. & Ullrich, A. Strategies to overcome resistance to targeted protein kinase inhibitors. Nature Rev. Drug Discov. 3, 1001–1010 (2004).
  Article CAS Google Scholar
• Zhou, B. B. et al. Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell 10, 39–50 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Koizumi, F., Shimoyama, T., Taguchi, F., Saijo, N. & Nishio, K. Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int. J. Cancer 116, 36–44 (2005).
  Article CAS PubMed Google Scholar
• Haber, D. A. & Settleman, J. Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class. Cell Cycle 4, 1057–1059 (2005).
  Article CAS PubMed Google Scholar
• Elkind, N. B. et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res. 65, 1770–1777 (2005).
  Article CAS PubMed Google Scholar
• Ozvegy-Laczka, C., Cserepes, J., Elkind, N. B. & Sarkadi, B. Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters. Drug Resist. Updat. 8, 15–26 (2005).
  Article PubMed CAS Google Scholar
• Yanase, K. et al. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol. Cancer Ther. 3, 1119–1125 (2004).
  CAS PubMed Google Scholar
• Nakamura, Y. et al. Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res. 65, 1541–1546 (2005).
  Article CAS PubMed Google Scholar
• Nagashima, S. et al. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer. Cancer Chemother. Pharmacol. 58, 594–600 (2006).
  Article CAS PubMed Google Scholar
• Kitazaki, T. et al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49, 337–343 (2005).
  Article PubMed Google Scholar
• Yang, C. H. et al. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein. Cancer Res. 65, 6943–6949 (2005).
  Article CAS PubMed Google Scholar
• Singh, J. et al. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases. J. Med. Chem. 40, 1130–1135 (1997).
  Article CAS PubMed Google Scholar
• Fry, D. W. et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl Acad. Sci. USA 95, 12022–12027 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Rabindran, S. K. et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 64, 3958–3965 (2004).
  Article CAS PubMed Google Scholar
• Wissner, A. et al. Synthesis and structure-activity relationships of 6, 7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2). J. Med. Chem. 46, 49–63 (2003).
  Article CAS PubMed Google Scholar
• Haber, D. A. et al. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb. Symp. Quant. Biol. 70, 419–426 (2005).
  Article CAS PubMed Google Scholar
• Discafani, C. M. et al. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387, 785). Biochem. Pharmacol. 57, 917–925 (1999).
  Article CAS PubMed Google Scholar
• Smaill, J. B. et al. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3, 2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J. Med. Chem. 43, 1380–1397 (2000).
  Article CAS PubMed Google Scholar
• Carter, T. A. et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl Acad. Sci. USA 102, 11011–11016 (2005). Details the development of second generation TKIs that overcome resistance that arises from mutations of the gatekeeper residue in various tyrosine kinase oncogenes.
  Article CAS PubMed PubMed Central Google Scholar
• Shimamura, T. et al. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res. 66, 6487–6491 (2006).
  Article CAS PubMed Google Scholar
• Ji, H. et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc. Natl Acad. Sci. USA 103, 7817–7822 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Shimamura, T., Lowell, A. M., Engelman, J. A. & Shapiro, G. I. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res. 65, 6401–6408 (2005).
  Article CAS PubMed Google Scholar
• Yang, S. et al. Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. Cancer Res. 66, 6990–6997 (2006).
  Article CAS PubMed Google Scholar
• Ge, J. et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J. Med. Chem. 49, 4606–4615 (2006).
  Article CAS PubMed Google Scholar
• Herbst, R. S., Fukuoka, M. & Baselga, J. Gefitinib–a novel targeted approach to treating cancer. Nature Rev. Cancer 4, 956–965 (2004).
  Article CAS Google Scholar
• Shaw, R. J. & Cantley, L. C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424–430 (2006).
  Article CAS PubMed Google Scholar
• Ihle, N. T. et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol. Cancer Ther. 4, 1349–1357 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Fan, Q. W. et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9, 341–349 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Goudar, R. K. et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol. Cancer Ther. 4, 101–112 (2005).
  CAS PubMed Google Scholar
• Rao, R. D. et al. Disruption of parallel and converging signaling pathways contributes to the synergistic antitumor effects of simultaneous mTOR and EGFR inhibition in GBM cells. Neoplasia 7, 921–929 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Doherty, L. et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67, 156–158 (2006).
  Article CAS PubMed Google Scholar
• Easton, J. B. & Houghton, P. J. Therapeutic potential of target of rapamycin inhibitors. Expert Opin. Ther. Targets 8, 551–564 (2004).
  Article CAS PubMed Google Scholar
• Margolin, K. et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104, 1045–1048 (2005).
  Article CAS PubMed Google Scholar
• Takeuchi, H. et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res. 65, 3336–3346 (2005).
  Article CAS PubMed Google Scholar
• Hay, N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8, 179–183 (2005).
  Article CAS PubMed Google Scholar
• Adjei, A. A. Novel combinations based on epidermal growth factor receptor inhibition. Clin. Cancer Res. 12, 4446s–4450s (2006).
  Article CAS PubMed Google Scholar
• Hennequin, L. F. et al. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J. Med. Chem. 45, 1300–1312 (2002).
  Article CAS PubMed Google Scholar
• Wedge, S. R. et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62, 4645–4655 (2002).
  CAS PubMed Google Scholar
• Ciardiello, F. et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin. Cancer Res. 10, 784–793 (2004).
  Article CAS PubMed Google Scholar
• Taguchi, F. et al. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ('Iressa')-sensitive and resistant xenograft models. Cancer Sci. 95, 984–989 (2004).
  Article CAS PubMed Google Scholar
• Traxler, P. et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 64, 4931–4941 (2004).
  Article CAS PubMed Google Scholar
• Lee, D. Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer. Clin. Lung Cancer 7, 89–91 (2005).
  Article PubMed Google Scholar
• Stephens, P. et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525–526 (2004).
  Article CAS PubMed Google Scholar
• Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268–274 (2006). Highlights the genetic complexity and inter-tumour variability of human cancers.
  Article CAS PubMed Google Scholar
• Ngo, V. N. et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441, 106–110 (2006). New approaches to anticancer target discovery.
  Article CAS PubMed Google Scholar
• Weinstein, I. B. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science 297, 63–64 (2002).
  Article CAS PubMed Google Scholar
• Weinstein, I. B. & Joe, A. K. Mechanisms of disease: Oncogene addiction-a rationale for molecular targeting in cancer therapy. Nature Clin. Pract. Oncol. 3, 448–457 (2006).
  Article CAS Google Scholar
• Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 2, 561–566 (1996).
  Article CAS PubMed Google Scholar
• Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468–472 (1999).
  Article CAS PubMed Google Scholar
• Fisher, G. H. et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15, 3249–3262 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Felsher, D. W. & Bishop, J. M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol. Cell 4, 199–207 (1999).
  Article CAS PubMed Google Scholar
• Felsher, D. W. Cancer revoked: oncogenes as therapeutic targets. Nature Rev. Cancer 3, 375–380 (2003).
  Article CAS Google Scholar
• Shigematsu, H. & Gazdar, A. F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int. J. Cancer 118, 257–262 (2006).
  Article CAS PubMed Google Scholar
• Balak, M. N. et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin. Cancer Res. 12, 6494–6500 (2006).
  Article CAS PubMed Google Scholar
• Asahina, H. et al. Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L. Lung Cancer 54, 419–422 (2006).
  Article PubMed Google Scholar
• Baselga, J. et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 20, 4292–4302 (2002).
  Article CAS PubMed Google Scholar
• Janmaat, M. L., Kruyt, F. A., Rodriguez, J. A. & Giaccone, G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin. Cancer Res. 9, 2316–2326 (2003).
  CAS PubMed Google Scholar
• Tracy, S. et al. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 64, 7241–7244 (2004).
  Article CAS PubMed Google Scholar